GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
Rating: GHDX
Buy $38

Genomic Health, Inc. (NASDAQ: GHDX) rated to Buy with price target $38 by UBS

Monday,  Nov 23, 2015  10:25 AM ET by Lynn Gilbert

UBS rated Genomic Health,
Inc. (NASDAQ: GHDX) to Buy with price target $38.

Genomic Health, Inc. is a life science company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. It launched its first test, Oncotype DX, which has been shown to predict the likelihood of breast cancer recurrence and chemotherapy benefit in early stage breast cancer patients. The Oncotype DX assay represents the first diagnostic gene expression test on the market that provides consistent results across multiple independent trials having breast cancer patients, including a large validation study of The New England Journal of Medicine.

UBS is the leading global wealth manager, a top tier investment banking and securities firm, and one of the largest global asset managers. In Switzerland, UBS is the market leader in retail and commercial banking. With headquarters in Zurich and Basel, Switzerland, UBS operates in over 50 countries and from all major international centers. UBS employs more than 80,000 people.



RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy